Jeska de Vries‐Bouwstra

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 612 citations · Full text

Autoimmune Disease, Systemic Scleroderma, Immunology +3

Systemic sclerosis: state of the art on clinical practice guidelines

Vanessa Smith, Carlo Alberto Scirè, Rosaria Talarico et al. · RMD Open · 2018 · 137 citations · Full text

Long noncoding RNA H19X is a key mediator of TGF-β–driven fibrosis

Elena Pachera, Shervin Assassi, Gloria A. Salazar et al. · Journal of Clinical Investigation · 2020 · 74 citations · Full text

Pathology, Tgf-β–driven Fibrosis, Key Mediator +20

Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study

Sandra van Bijnen, Jeska de Vries‐Bouwstra, C.H.M. van den Ende et al. · Annals of the Rheumatic Diseases · 2020 · 52 citations

Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis

Tobias Messemaker, Loubna Chadli, Guoshuai Cai et al. · Journal of Investigative Dermatology · 2017 · 50 citations · Full text

Autoimmune Disease, Skin Tissue, Systemic Scleroderma +11